Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous ribonucleic acid (RNA) refers to the complete set of RNA molecules naturally produced by a cell's transcriptional machinery, including coding sequences like messenger RNA (mRNA) and non-coding varieties such as microRNA (miRNA) and long non-coding RNA (lncRNA) (Source: Nature Reviews Genetics, 2014). These molecules are fundamental to cellular life, acting as the intermediary template for protein synthesis and serving as sophisticated regulators of gene expression and architectural scaffolds within the nucleus and cytoplasm (Source: Molecular Biology of the Cell, 6th Ed). Pathological alterations in endogenous RNA—such as point mutations, aberrant splicing, or over-expression—underlie a vast array of human diseases, including genetic disorders, cancers, and neurodegenerative conditions (Source: Nature Reviews Drug Discovery, 2020). As a therapeutic target, endogenous RNA offers a way to intervene in disease processes that are "undruggable" at the protein level. Modern pharmacology utilizes antisense oligonucleotides (ASOs), siRNA, and RNA-binding small molecules to selectively degrade toxic transcripts, restore functional protein production through splicing correction, or silence overactive genes, thereby providing highly specific precision medicine approaches (Source: Journal of Medicinal Chemistry, 2021).
Antisense oligonucleotides (ASOs) bind to target RNA to induce RNase H-mediated degradation or modulate splicing; small interfering RNAs (siRNAs) utilize the RISC complex for targeted mRNA cleavage; small molecules can bind to RNA secondary structures to inhibit translation or modify splicing (Source: Nature Reviews Drug Discovery, 2020).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endogenous ribonucleic acid (RNA) (RNA).